Navigation Links
Isis Pharmaceuticals to Present at the 2013 Deutsche Bank BioFEST
Date:11/25/2013

CARLSBAD, Calif., Nov. 25, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2013 Deutsche Bank BioFEST on Monday, December 2, 2013 at 8:25 a.m. ET in Boston, MA.

(Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO)

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 31 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

Forward-Looking Statements
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.  In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... IBM (NYSE: IBM ) has been recognized as a ... for the fourth year in a row. 1 ... the Leaders quadrant have the highest scores for their Ability ... Leaders quadrant has the market share, credibility, and marketing and ... These vendors demonstrate a clear understanding of market needs; they ...
(Date:7/21/2017)... and RESEARCH TRIANGLE PARK, N.C. ... Corporation (NASDAQ: UTHR ) announced today that ... before the market opens on Thursday, July 27, 2017. ... host a teleconference on Thursday, July 27, 2017, at ... dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast ...
(Date:7/20/2017)... , July 20, 2017  Prime Therapeutics LLC (Prime) released ... , M.D., following today,s Institute for Clinical and Economic Review,s ... on the effectiveness and value of abuse-deterrent formulations (ADF) of ... policy roundtable at the meeting. ... material cost benefit to the use of abuse-deterrent formulations (ADF) ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be partnering with ... to schedule an appointment online in real time,” said Keith English, LocalMed CEO. “Allowing ... directory will bring more Six Month Smiles patients to their providers.” , Each month, ...
(Date:7/26/2017)... ... July 26, 2017 , ... Isodiol ... global cannabis innovator, specializing in the development of pharmaceutical and consumer products, announces ... 2017 to June 30, 2017. Iso International LLC recorded unaudited fiscal Q1 profits ...
(Date:7/26/2017)... ... 26, 2017 , ... BioPlus Specialty Pharmacy (BioPlus), ... of the HCV Treatment Path app (version 4.4.0) to keep health care providers ... All of the latest HCV medications are included in this app, including Vosevi™ ...
(Date:7/25/2017)... , ... July 25, 2017 , ... Summers in Palm ... the air conditioner — think homemade gourmet ice cream, sparkling pools, and mile-high fun. ... shop featuring fun mugs, journals, and other must-have knick knacks. Ice cream and sorbet ...
(Date:7/25/2017)... ... July 25, 2017 , ... SureVest Insurance ... services to communities across North Carolina, is launching a charity event in conjunction ... support for the ongoing fight against bladder cancer. , The Bladder Cancer Advocacy ...
Breaking Medicine News(10 mins):